Teriflunomide May Delay Onset of MS Symptoms in People With RIS

A recent Phase 3 trial showed people with radiologically isolated syndrome (RIS) who took Aubagio were 72 percent less likely to later develop MS symptoms.

Related Keywords

Connecticut ,United States ,Winston Salem ,North Carolina ,New Haven ,Boston ,Massachusetts ,France ,American ,Erin Longbrake ,Christine Lebrun Frenay ,Lebrun Frenay ,Scott Otallah ,American Academy Of Neurology ,Drug Administration ,University Hospital Of Nice ,Atrium Health Wake Forest Baptist ,American Academy ,Annual Meeting ,University Hospital ,Taking Teriflunomide Had ,Lower Risk ,Experiencing First ,Systematically Screen ,Yale Medicine ,Multiple Sclerosis ,Talk With Your Doctor About ,